About Tarlatamab

Underlined terms can be clicked for more information.

What is tarlatamab?

tarlatamab BiTE molecule graphic

Tarlatamab is a type of drug called a bispecific T-cell engager, or BiTE® molecule, that has two key parts: a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells.

Tarlatamab is a type of immunotherapy that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.

Tarlatamab finding t-cells and cancer cells

Tarlatamab moves throughout the body finding T-cells and cancer cells

Tarlatamab attaching to a T-cell and a cancer cell

Tarlatamab attaches to a T-cell and a cancer cell and brings them close together

Tarlatamab enabling the T-cell to attack the cancer cell

Tarlatamab enables the T-cell to attack the cancer cell, which stimulates the T-cell to multiply and attack other cancer cells

How can I participate in a clinical trial with tarlatamab?

For patients with extensive-stage SCLC receiving their first course of treatment. Patients with prior limited-stage SCLC may qualify.

For patients with limited-stage SCLC who have completed chemotherapy and radiation therapy without progression.

If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.

phone graphic

Where can I get more information?

To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.

AmgenMedInfo.com

866-572-6436

Monday - Friday 8am to 8pm (ET)

Contact Amgen